SMPD1 and plasma cell myeloma: Our results are in agreement with previous data describing the development of myeloma in patients with congenital sphingolipidoses, and suggest that imbalances in the formation of ceramide, SFO, SFA, S1P, end enzymes activity, such as aSMase, may affect the development of the disease and change as a result of its treatment.